Browse
Prediction results retrieved after performance evaluation of WHO approved 34 primers to estimate their binding affinities for 3892 SARS-CoV-2 variants.

Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used
  
FL.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FY.1.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FY.1.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XDBNUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XDBNUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GA.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GA.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.35NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.35NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GM.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GM.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FL.3.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FL.3.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.44NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.44NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FU.3.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FU.3.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FV.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FV.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GJ.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GJ.1.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EG.5.2.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.5.2.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HK.27NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.27NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HK.30NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.30NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HK.1NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.1NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
EG.5.1.17NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
EG.5.1.17NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.16.12NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.16.12NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.46NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.46NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
GB.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
GB.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.1.5.72NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
XBB.1.5.72NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FY.5NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FY.5NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FY.1.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FY.1.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HH.2NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HH.2NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
HK.29NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
HK.29NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
FY.3.3NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
FY.3.3NUS-CDC-N-2GCGCGACATTCCGAAGAA1855.562923029213R-21404.2US
XBB.2.3.8NUS-CDC-N-2TTACAAACATTGGCCGCAAA20402916429183F-21115.5US
Lineage
(WHO label)
  
Target Gene
  
Primer Name
  
Primer Sequence
  
Primer Length
  
Primer GC Content (%)
  
Start Position
  
End Position
  
Primer Direction
  
ΔG (cal)
  
Primer first used